Off-label drugs for the treatment of lupus symptoms represents the standard of care for people with lupus, but current regulations make it difficult for doctors and manufacturers to communicate. Read Sandra C. Raymond's remarks now.
Further studies may lead to interventions that improve the health outcomes of people with lupus.
Results from a study of epratuzumab were released today. It did not meet its primary endpoint of clinically reducing the severity of lupus in people with mild to moderate disease. The following is a statement from Sandra C. Raymond, President and CEO
Lupus Foundation of America Hosts Capitol Conversation on 21st Century Cures Moderated by Chuck Todd
National Advocacy Awards Dinner recognizes leaders from Congress, federal agencies, industry and the research community.
Lupus Foundation of America Hosts Awards Dinner & 21st Century Cures Discussion
Lupus is an autoimmune disease in which people generate antibodies against their own organs. But when antibodies to phospholipid-binding proteins are involved, a variety of complications can occur.
People with lupus need and deserve a full arsenal of treatments. With many new and innovative drugs for lupus in the drug pipeline, these highly anticipated treatments will mean nothing if people with lupus cannot afford them.
A new research study by Foundation grantee Dr. Laurence Morel identifies a lupus related gene that affects adult mesenchymal stem cells. Read more.